Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 1, 2010, Pages 40-46

  Cogle, Christopher R ^a   Imanirad, Iman ^a   Wiggins, Laura E ^b   Hsu, Jack ^a   Brown, Randy ^a   Scornik, Juan C ^a   Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Azanucleoside; Chimerism; Hematopoietic cell transplantation; Hypomethylation; Induction therapy; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; IDARUBICIN; MELPHALAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CELL LINEAGE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; GRANULOCYTE; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; REDUCED INTENSITY CONDITIONING; RELAPSE; REMISSION; WHOLE BODY RADIATION;

AZACITIDINE; ENZYME INHIBITORS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; NEOADJUVANT THERAPY; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CHIMERA;

EID: 76149131707     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood. 2002;100:2957-2964.
2. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903.
3. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-1803.
4. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-57.
5. Fenaux P, Mufti GJ, Santini V, et al. Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimens: results of the AZA-001 phase III study. Blood (ASH Annual Meeting Abstracts). 2007;110:817a.
6. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110:620-630.
7. Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, Appelbaum FR. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol. 2001;19:2134-2141.
8. Sierra J, Pérez WS, Rozman C, et al. Bone marrow transplantation from HLAidentical siblings as treatment for myelodysplasia. Blood. 2002;100:1997-2004.
9. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002; 100:1201-1207.
10. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow trans plantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943-1951.
11. Deeg HJ, Guardiola P. Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis. Int J Hematol. 2002; 76(suppl 2):29-34.
12. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT) - specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912-2919.
13. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25:4246-4254.
14. Platzbecker U, Bornhäuser M, Germing U, et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant. 2008;14:1217-1225.
15. Warlick ED, Cioc A, DeFor T, Dolan M, Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pre-transplant disease burden. Biol Blood Marrow Transplant. 2009;15:30-38.
16. Appelbaum FR, Barrall J, Storb R, et al. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med. 1990;112:590-597.
17. Anderson JE, Anasetti C, Appelbaum FR, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol. 1996;93:59-67.
18. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle. Blood. 1996;88:358-365.
19. Yakoub-Agha I, de La Salmonière P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients - report of the French Society of Bone Marrow Transplantation. J Clin Oncol. 2000;18:963-971.
20. Oosterveld M, Suciu S, Verhoef G, et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia. 2003;17:859-868.
21. Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia. 2005;19:396-401.
22. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579-585.
23. De Padua Silva L, de Lima M, Kantarjian H, et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant. 2009;43:839-843.
24. Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009. [Epub ahead of print.] doi: 10.1038/bmt.2009.134.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
27. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reducedintensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836-846.